Immuno-SPECT imaging of aberrant p53 expression in pancreatic ductal adenocarcinoma

Immuno-SPECT imaging of aberrant p53 expression in pancreatic ductal adenocarcinoma

<p>Pancreatic ductal adenocarcinoma (PDAC) is a notoriously ferocious malignancy arising from the head of the pancreas, with aggressive biology and early-onset metastases. PDAC develop and progress asymptomatically with over 80% of the patients presenting for diagnosis with inoperable metastat...

Szczegółowa specyfikacja

Opis bibliograficzny
1. autor:	Alakonya, H
Kolejni autorzy:	Cornelissen, B
Format:	Praca dyplomowa
Język:	English
Wydane:	2023

Podobne zapisy

Imaging p53 in pancreatic ductal adenocarcinoma
od: Koustoulidou, S
Wydane: (2017)

Imaging p53 in Pancreatic Ductal Adenocarcinoma (PDAC)
od: Koustoulidou, S, i wsp.
Wydane: (2016)

Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Metaanalysis of transcriptional subtypes
od: De Santiago, I, i wsp.
Wydane: (2018)

Ubiquitous Aberration in Cholesterol Metabolism across Pancreatic Ductal Adenocarcinoma
od: Venugopal Gunda, i wsp.
Wydane: (2022-01-01)

Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma
od: Yunzhen Qian, i wsp.
Wydane: (2022-06-01)

Molecular imaging of pancreatic ductal adenocarcinoma
od: Wei Huang, i wsp.
Wydane: (2023-10-01)

Expression of p53, p16 and Ki67 proteins in ductal adenocarcinoma of the pancreatic head and their relation with survival and cell differentiation
od: Mário Benjamin Goitia-Durán, i wsp.
Wydane: (2010-12-01)

The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells
od: Giovanna Butera, i wsp.
Wydane: (2020-06-01)

Immuno-imaging of ICAM-1 in tumours by SPECT
od: Mosley, M, i wsp.
Wydane: (2020)

Immuno-Imaging (PET/SPECT)–Quo Vadis?
od: Carsten S. Kramer, i wsp.
Wydane: (2022-05-01)

MORPHOLOGICAL AND EXPRESSION FEATURES OF DUCTAL PANCREATIC ADENOCARCINOMA
od: Yu. Yu. Rakina, i wsp.
Wydane: (2017-09-01)

P53 expression in invasive pancreatic adenocarcinoma and precursor lesions
od: Norfadzilah, M.Y., i wsp.
Wydane: (2011)

Evaluation of microvessel density and p53 expression in pancreatic adenocarcinoma
od: Ricardo Jureidini, i wsp.

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
od: Sameer A Dhayat, i wsp.
Wydane: (2015-01-01)

Autophagy Blockage Reduces the Incidence of Pancreatic Ductal Adenocarcinoma in the Context of Mutant Trp53
od: Laura Mainz, i wsp.
Wydane: (2022-03-01)

THE SUBTYPES OF PANCREATIC DUCTAL ADENOCARCINOMAS
od: Apeksha Kakkar, i wsp.
Wydane: (2016-12-01)

Syndecans and Pancreatic Ductal Adenocarcinoma
od: Nausika Betriu, i wsp.
Wydane: (2021-02-01)

Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma.
od: Kimberly A Kelly, i wsp.
Wydane: (2008-04-01)

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status
od: E.B. Faber, i wsp.
Wydane: (2024-06-01)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
od: Raffaele Pezzilli, i wsp.
Wydane: (2011-07-01)

Aberrant overexpression of vascular endothelial growth factor in pancreatic ductal adenocarcinoma is associated with aggressive clinical behavior
od: Naomi Y Jiang, i wsp.
Wydane: (2010-07-01)

The Importance of Stroma and Stromal SMA Expression in Pancreatic Ductal Adenocarcinoma
od: Gamze AKBAS, i wsp.
Wydane: (2024-09-01)

Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma
od: Katsunori Matsushita, i wsp.
Wydane: (2022-10-01)

Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
od: Dingyuan Hu, i wsp.
Wydane: (2019-02-01)

The T cell architecture of pancreatic ductal adenocarcinoma
od: Sivakumar, S, i wsp.
Wydane: (2019)

The T-cell architecture of pancreatic ductal adenocarcinoma
od: Sivakumar, S, i wsp.
Wydane: (2019)

Ubiquitin signaling in pancreatic ductal adenocarcinoma
od: Shengnan Lv, i wsp.
Wydane: (2023-12-01)

Oral mycobiota and pancreatic ductal adenocarcinoma
od: Ailin Wei, i wsp.
Wydane: (2022-12-01)

Apoptotic pathways in pancreatic ductal adenocarcinoma
od: Saur Dieter, i wsp.
Wydane: (2008-07-01)

Metabolism remodeling in pancreatic ductal adenocarcinoma
od: Jin-Tao Li, i wsp.
Wydane: (2019-11-01)

Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
od: Sofia Parrasia, i wsp.
Wydane: (2021-01-01)

ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway
od: Zuyi Ma, i wsp.
Wydane: (2022-04-01)

Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma.
od: Ole Helm, i wsp.
Wydane: (2014-01-01)

Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
od: Yasuki Hori, i wsp.
Wydane: (2015-01-01)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
od: Sumit Sahni, i wsp.
Wydane: (2023-09-01)

Expression of epidermal growth factors and apoptosis markers in pancreatic ductal adenocarcinoma.
od: Jolanta Czyzewska, i wsp.
Wydane: (2010-05-01)

Circular RNA Expression Profile of Pancreatic Ductal Adenocarcinoma Revealed by Microarray
od: Haimin Li, i wsp.
Wydane: (2016-12-01)

Microarray expression profile of circular RNAs in human pancreatic ductal adenocarcinoma
od: Shibin Qu, i wsp.
Wydane: (2015-09-01)

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma.
od: Michael Tayao, i wsp.
Wydane: (2016-01-01)

Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma: CT and MR imaging for differentiation
od: Wolfgang Schima, i wsp.
Wydane: (2020-07-01)